Sio Capital Remains Bullish On These Stocks Despite Weak Performance

As a healthcare-focused fund, Michael Castor‘s Sio Capital registered a terrible 2016, as it lost 18.7% net, compared to the 12% gain registered by the S&P 500 and the 8.3% drop of the MSCI World Healthcare Index. In its annual letter, the investor said that two main factors for the weak performance were speculative investments, and two “outliers” which were among the top detractors.

One of these detractors was Quotient Ltd (NASDAQ:QTNT), with other detractors including Adamis Pharmaceuticals Corp (NASDAQ:ADMP) and Pfenex Inc (NYSEMKT:PFNX). On the other hand, among the positions that had a positive contribution to Sio Capital’s returns last year were Amgen, Inc. (NASDAQ:AMGN) and ChemoCentryx Inc (NASDAQ:CCXI). Further in this article, we are going to take a closer look at the fund’s comments regarding these stocks.

In the long-run, Sio Capital thinks that gene sequencing will represent a good investment opportunity in the future as the procedure will become more affordable and companies will be able to use the data in a more effective way. In terms of healthcare policy, Sio Capital expects that Republicans and President Trump won’t “repeal” the Affordable Care Act (Obamacare), but will rather implement a number of changes to the policy.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

In Quotient Ltd (NASDAQ:QTNT), Sio Capital held some 2.24 million shares worth $10.83 million at the end of December, according to its latest 13F. The fund has held shares of the diagnostics company since the fourth quarter of 2014 and has previously discussed the stock in its letters. Michael Castor’s fund pointed out the 50% drop registered by the stock in October on the back of news that some of Quotient’s antigen tests were not “performing adequately”. However, it thought that the company would overcome those challenges, which Quotient did as it reported in January. Quotient Ltd (NASDAQ:QTNT) is developing tests as part of its MosaiQ platform for patients in need of blood transfusions. It plans to register the platform in Europe in June and in the U.S. four months later.

“QTNT faced headwinds this year as they needed to raise cash at approximately the same time that a large institutional shareholder closed its business and sold its large QTNT share holdings (this saturated market demand and weighed on price). Finally, Quotient’s disclosure of their problems (now solved) transitioning from R&D-scale to commercial-scale manufacturing led to this stock’s terrible performance. Quotient remains one of the positions about which we are most enthusiastic. Liquidity has increased. We will be prudent about trimming our position to reflect our enthusiasm while still holding an appropriate weight,” Sio Capital said.

Among the funds we track, the number of investors bullish on Quotient Ltd (NASDAQ:QTNT) inched down by two to nine; these funds held nearly 31% of the company’s outstanding stock heading into 2017.

In Adamis Pharmaceuticals Corp (NASDAQ:ADMP), Sio Capital raised its stake by 57% on the quarter to 1.05 million shares worth $3.31 million held at the end of the year. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is developing a number of drug-device combinations, including an Epinephrine pre-filled syringe, which will compete with Mylan’s Epipen. The investor is betting that Adamis’ approval for the syringe will be announced in June. Taking into account the approval of the product this year, as well as Adamis’ progress in other segments, pipeline products, as well as financing decisions. In this way, the fund has a price target of $12-$15 for Adamis Pharmaceuticals Corp (NASDAQ:ADMP).

On the next page, we are going to take a closer look at two contributors to Sio’s returns, as well as one company in which the fund liquidated its stake last quarter.